Last reviewed · How we verify
Radiopaque Implanon
Radiopaque Implanon is a subdermal contraceptive implant containing etonogestrel that provides long-acting reversible contraception by suppressing ovulation through progestin delivery.
Radiopaque Implanon is a subdermal contraceptive implant containing etonogestrel that provides long-acting reversible contraception by suppressing ovulation through progestin delivery. Used for Long-acting reversible contraception in women of reproductive age.
At a glance
| Generic name | Radiopaque Implanon |
|---|---|
| Sponsor | Organon and Co |
| Drug class | Progestin-only contraceptive |
| Target | Progesterone receptor |
| Modality | Small molecule |
| Therapeutic area | Contraception |
| Phase | Phase 3 |
Mechanism of action
Implanon is a single flexible plastic rod measuring 3 cm in length that is inserted subdermally in the upper arm. It releases etonogestrel, a synthetic progestin, at a controlled rate over three years. The progestin works by inhibiting the LH surge necessary for ovulation, thickening cervical mucus to impede sperm transport, and altering the endometrium. The 'radiopaque' formulation contains barium sulfate to make the implant visible on X-rays for easier localization during removal.
Approved indications
- Long-acting reversible contraception in women of reproductive age
Common side effects
- Irregular bleeding/amenorrhea
- Headache
- Acne
- Breast tenderness
- Insertion site pain/infection
Key clinical trials
- A Study to Assess Contraceptive Efficacy and Safety of Etonogestrel (ENG) Implant Beyond 3 Years of Use (MK-8415-060) (PHASE3)
- Impact of Contraceptives on Cervico-Vaginal Mucosa (PHASE4)
- A Bioequivalence Study of IMPLANON and Radiopaque IMPLANON (34528)(P05720) (PHASE3)
- Antepartum Etonogestrel Contraceptive Implant Insertion at Term (PHASE1)
- Immediate Postpartum Nexplanon Placement in Opioid Dependent Women
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Radiopaque Implanon CI brief — competitive landscape report
- Radiopaque Implanon updates RSS · CI watch RSS
- Organon and Co portfolio CI